BMY logo Bristol-Myers Squibb Company +
Bristol-Myers Squibb Company
+

Bristol-Myers Squibb Company (BMY) Business News

Track Bristol-Myers Squibb Company in real time with a live news feed covering Bristol-Myers Squibb Company stock news, official press releases, company announcements, and an archive of historical Bristol-Myers Squibb Company news. ...more

  • Calendar
    Years
    Get instant access
    Sign up for free
    Get instant access
    Sign up for free
    Month
    Jan
    Feb
    Mar
    Apr
    May
    Jun
    Jul
    Aug
    Sep
    Oct
    Nov
    Dec
    Date
    Su
    Mo
    Tu
    We
    Th
    Fr
    Sa
    Selected Filter
    No selection

Bristol Myers drug delays myeloma progression in hard to treat patients

Reuters

8:02 AM | Friday | May 29, 2026

news photo
Loading...

Bristol Myers Squibb said on Friday that its experimental oral drug mezigdomide delayed disease progression in a late-stage trial of multiple myeloma patients whose illness had relapsed ​or not responded to other treatments.

Read full article redirect
8:02 AM | Friday | May 29, 2026

Bristol Myers drug delays myeloma progression in hard to treat patients

Reuters

Bristol Myers Squibb said on Friday that its experimental oral drug mezigdomide delayed disease progression in a late-stage trial of multiple myeloma patients whose illness had relapsed ​or not responded to other treatments.

Read full article arrow
News Thumbnail
8:00 AM | Friday | May 29, 2026

How Bristol Is Building On Its $74 Billion Celgene Buyout With New 'Molecular Glue'

Investors Business Daily

Bristol Myers Squibb said Friday its drug, mezigdomide, lowered the risk of progression or death for multiple myeloma patients by over half.

Read full article arrow
News Thumbnail
8:00 AM | Friday | May 29, 2026

Bristol Myers Squibb Announces CELMoD Mezigdomide Reduces Risk of Disease Progression or Death by More than 50% vs. Standard of Care in Relapsed or Refractory Multiple Myeloma

Business Wire

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ASCO--BMS Announces CELMoD Mezigdomide Reduces Risk of Disease Progression or Death by More than 50% vs. Standard of Care in.

Read full article arrow
News Thumbnail
10:09 AM | Wednesday | May 27, 2026

Bristol-Myers Squibb Is Quietly Building Its Next Growth Cycle

Seeking Alpha

Bristol-Myers Squibb Company sees its business tracking toward the upper end of full-year 2026 revenue and EPS guidance ranges. In my view, this primarily reflects strong demand for Breyanzi, Camzyos, and Reblozyl. Sales of this "trio" were $1.28 billion in Q1, up 42.2% year-over-year.

Read full article arrow
News Thumbnail
6:59 AM | Wednesday | May 27, 2026

Bristol Myers Squibb to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

Business Wire

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference.

Read full article arrow
News Thumbnail
10:40 AM | Tuesday | May 26, 2026

Here's Why Bristol Myers Squibb (BMY) is a Strong Value Stock

Zacks Investment Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Read full article arrow
News Thumbnail
5:50 AM | Sunday | May 24, 2026

Looking to Buy Bristol Myers Squibb Stock on the Dip? Read This First.

The Motley Fool

Bristol Myers Squibb faces a daunting patent cliff. The company has a promising growth portfolio, but it may not be able to fully offset losses from older drugs.

Read full article arrow
News Thumbnail
7:05 AM | Thursday | May 21, 2026

The Most Undervalued Healthcare Stock in the S&P 500 Right Now

Fool - Investing News

The market appears to be short-sighted.

Read full article arrow
News Thumbnail
7:49 AM | Wednesday | May 20, 2026

Bristol Myers to deploy Anthropic's Claude AI model to speed up drug discovery

Reuters

Bristol Myers Squibb said on Wednesday it is partnering with Anthropic to make ​its Claude AI model available to ‌over 30,000 employees in an effort to accelerate the discovery, development and delivery of new medicines.

Read full article arrow
News Thumbnail
6:59 AM | Wednesday | May 20, 2026

Bristol Myers Squibb Announces Strategic Agreement with Anthropic to Position Claude Enterprise as the Shared Intelligence Platform Across Its Global Operations

Business Wire

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY--Bristol Myers Squibb Announces Strategic Agreement with Anthropic to Position Claude Enterprise as the Shared Intelligence Platform Across.

Read full article arrow
News Thumbnail